MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients.

Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and...

Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and...

Up to a million people in the UK live with heart failure, a condition that reduces quality of life and increases the risk of hospital admission.

Recent research from scientists at Northwestern University has brought to light serious concerns about the safety of two widely prescribed drugs for...

Recent research from scientists at Northwestern University has brought to light serious concerns about the safety of two widely prescribed drugs for...

A recent study confirms that replacing saturated fats from dairy with plant-based unsaturated fats significantly reduces cardiometabolic risks. The...

PLAINSBORO, N.J., Aug. 30, 2024 /PRNewswire/ -- Today, The Lancet published a new pooled, participant-level analysis of patients with heart failure...

PLAINSBORO, N.J., Aug. 30, 2024 /PRNewswire/ -- Today, The Lancet published a new pooled, participant-level analysis of patients with heart failure...

Finerenone is effective in decreasing the incidence of heart failure and cardiovascular mortality. This finding has been reported based on a...